Mozobil (Plerixafor) for Myeloma | MyMyelomaTeam

Connect with others who understand.

sign up Log in
About MyMyelomaTeam
Powered By

Mozobil is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma and non-Hodgkin lymphoma. Mozobil is also known by its drug name, plerixafor.

Mozobil is a member of a class of drugs called hematopoietic stem cell mobilizers. Mozobil is believed to work by causing hematopoietic stem cells (blood cell stem cells) to move from the bone marrow into the blood circulation so they can be collected for transplantation in people with multiple myeloma.

How do I take it?
Prescribing information states that Mozobil is given as a subcutaneous (under your skin) injection by a healthcare professional. Mozobil is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Mozobil is available only as a subcutaneous injection.

Side effects
The FDA-approved label for Mozobil lists common side effects including diarrhea, nausea, fatigue, injection site reactions, headache, joint pain, dizziness, and vomiting.

Rare but serious side effects listed for Mozobil include spleen rupture and fetal harm.

For more details about this treatment, visit:

Mozobil — Sanofi-Aventis

Plerixafor — National Cancer Institute

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in